清热解毒方治疗宫颈高危型人乳头瘤病毒感染的临床研究

Clinical Study of Qingre Jiedu Prescription in Treatment of High-risk Human Papllimavirus Infection of Cervix

目的观察清热解毒方治疗宫颈高危型人乳头瘤病毒(HR-HPV)感染的临床疗效。方法选择宫颈高危型HPV感染患者123例,随机分为观察组62例,对照组61例。观察组用清热解毒方治疗,对照组用重组人干扰素α2b阴道泡腾胶囊治疗。两组均为置入阴道治疗,隔日1次,20天为1个疗程,共治疗3个疗程。对两组患者阴道局部用药前后的宫颈HPV病毒检测(HC2)、液基薄层细胞学检测(LCT)观察疗效,同时观察两组不良反应情况。结果与治疗前比较,两组LCT结果正常患者增多,炎性反应、ASCUS、LSIL患者减少,两组比较差异无统计学意义(χ~2=1.293,P>0.05)。观察组总有效率为87.1%(54/62),高于对照组[68.9%(42/61),P<0.05];同时观察组转阴率[53.2%(33/62)]高于对照组[32.8%(20/61),P<0.05]。观察组治疗期间未出现阴道不适及全身不良反应,对照组治疗期间2例患者自述阴道瘙痒,症状较轻微,未行特殊处理,未发生严重的药物不良反应。结论清热解毒方可以显著降低高危型HPV病毒载量,对于HPV转阴疗效确切,并且临床使用安全可靠,无不良反应。

Objective To observe the clinical efficacy of Qingre Jiedu prescription in treatment of cervical high-risk human papllimavirus（ HR-HPV） infection. Methods Totally 123 cases of patients with cervical high-risk HPV infection were randomly assigned to the observation group（ 62 cases） and the control group（ 61 cases）. The patients in the observation group were given Qingre Jiedu prescription,while patients in control group were given recombinant human interferon α2 b vaginal effervescent capsule,both received vaginal medication,once every other day. Twenty days as one therapeutic course,3 course in total. The HPV viral load was detected with Hybrid Capture 2（ HC2）. The changes of HPV viral load and the detective results by the Liquid-Based Cytology Test（ LCT） before and after the medication were observed,and the adverse reactions were observed. Results Compared with before treatment in the same group,the number of patients with normal LCT results increased,and the number of patients with inflammatory response,atypical squamous cells of undetermined significance（ ASCUS） and low-grade squamous intraepithelial lesion（ LSIL） decreased,but there was no significant difference（ χ~2= 1. 293,P〈0. 05）. After 3-months-medication,the total effective rate of reducing HPV viral load of the observation group [87. 1%（ 54/62） ]was significantly higher than that of the control group [68. 9%（ 42/61）,P〈0. 05]. The negative rate of the observation group [53. 2%（ 33/62） ] was significantly higher than that of the control group [32. 8%（ 20/61）,P〈0. 05]. There was no vaginal discomfort and systemic adverse reactions in the observation group during the treatment. In the control group,two patients had vaginal itching,mild symptoms and no serious adverse drug reactions occurred.Conclusions Qingre Jiedu prescription could reduce HR-HPV viral load and has reliable negative conversion effect. Qingre Jiedu prescription has exact curative effect on cervical HPV infection without any adverse reaction.